Cargando…
Animal Models for Target Diseases in Gene Therapy — using DNA and siRNA Delivery Strategies
Nanoparticles, including lipopolyamines leading to lipoplexes, liposomes, and polyplexes are targeted drug carrier systems in the current search for a successful delivery system for polynucleic acids. This review is focused on the impact of gene and siRNA delivery for studies of efficacy, pharmacody...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088656/ https://www.ncbi.nlm.nih.gov/pubmed/18841450 http://dx.doi.org/10.1007/s11095-008-9646-8 |
_version_ | 1783509583057125376 |
---|---|
author | Blagbrough, Ian S. Zara, Chiara |
author_facet | Blagbrough, Ian S. Zara, Chiara |
author_sort | Blagbrough, Ian S. |
collection | PubMed |
description | Nanoparticles, including lipopolyamines leading to lipoplexes, liposomes, and polyplexes are targeted drug carrier systems in the current search for a successful delivery system for polynucleic acids. This review is focused on the impact of gene and siRNA delivery for studies of efficacy, pharmacodynamics, and pharmacokinetics within the setting of the wide variety of in vivo animal models now used. This critical appraisal of the recent literature sets out the different models that are currently being investigated to bridge from studies in cell lines through towards clinical reality. Whilst many scientists will be familiar with rodent (murine, fecine, cricetine, and musteline) models, few probably think of fish as a clinically relevant animal model, but zebrafish, madake, and rainbow trout are all being used. Larger animal models include rabbit, cat, dog, and cow. Pig is used both for the prevention of foot-and-mouth disease and human diseases, sheep is a model for corneal transplantation, and the horse naturally develops arthritis. Non-human primate models (macaque, common marmoset, owl monkey) are used for preclinical gene vector safety and efficacy trials to bridge the gap prior to clinical studies. We aim for the safe development of clinically effective delivery systems for DNA and RNAi technologies. |
format | Online Article Text |
id | pubmed-7088656 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-70886562020-03-23 Animal Models for Target Diseases in Gene Therapy — using DNA and siRNA Delivery Strategies Blagbrough, Ian S. Zara, Chiara Pharm Res Expert Review Nanoparticles, including lipopolyamines leading to lipoplexes, liposomes, and polyplexes are targeted drug carrier systems in the current search for a successful delivery system for polynucleic acids. This review is focused on the impact of gene and siRNA delivery for studies of efficacy, pharmacodynamics, and pharmacokinetics within the setting of the wide variety of in vivo animal models now used. This critical appraisal of the recent literature sets out the different models that are currently being investigated to bridge from studies in cell lines through towards clinical reality. Whilst many scientists will be familiar with rodent (murine, fecine, cricetine, and musteline) models, few probably think of fish as a clinically relevant animal model, but zebrafish, madake, and rainbow trout are all being used. Larger animal models include rabbit, cat, dog, and cow. Pig is used both for the prevention of foot-and-mouth disease and human diseases, sheep is a model for corneal transplantation, and the horse naturally develops arthritis. Non-human primate models (macaque, common marmoset, owl monkey) are used for preclinical gene vector safety and efficacy trials to bridge the gap prior to clinical studies. We aim for the safe development of clinically effective delivery systems for DNA and RNAi technologies. Springer US 2008-10-08 2009 /pmc/articles/PMC7088656/ /pubmed/18841450 http://dx.doi.org/10.1007/s11095-008-9646-8 Text en © Springer Science+Business Media, LLC 2008 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Expert Review Blagbrough, Ian S. Zara, Chiara Animal Models for Target Diseases in Gene Therapy — using DNA and siRNA Delivery Strategies |
title | Animal Models for Target Diseases in Gene Therapy — using DNA and siRNA Delivery Strategies |
title_full | Animal Models for Target Diseases in Gene Therapy — using DNA and siRNA Delivery Strategies |
title_fullStr | Animal Models for Target Diseases in Gene Therapy — using DNA and siRNA Delivery Strategies |
title_full_unstemmed | Animal Models for Target Diseases in Gene Therapy — using DNA and siRNA Delivery Strategies |
title_short | Animal Models for Target Diseases in Gene Therapy — using DNA and siRNA Delivery Strategies |
title_sort | animal models for target diseases in gene therapy — using dna and sirna delivery strategies |
topic | Expert Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088656/ https://www.ncbi.nlm.nih.gov/pubmed/18841450 http://dx.doi.org/10.1007/s11095-008-9646-8 |
work_keys_str_mv | AT blagbroughians animalmodelsfortargetdiseasesingenetherapyusingdnaandsirnadeliverystrategies AT zarachiara animalmodelsfortargetdiseasesingenetherapyusingdnaandsirnadeliverystrategies |